New trial
Spotlight
Phase Ib/II ZL-1310: DLL3-targeted Topoisomerase I inhibitor in selected solid tumors.
- Trial ID
- NCT06885281 on ClinicalTrials.gov
- Cancer type
- Neuroendocrine Tumor
- Stage of research
- Exploratory
- Location
- 8 Locations
- Published in
- New in Oncology - July 3, 2025
This multi-center, open-label trial from Zai Lab (Shanghai) is assessing ZL-1310 as a single-agent therapy in patients with neuroendocrine carcinomas progressing after platinum therapy. The study is conducted at sites in the US and China to evaluate safety and preliminary efficacy.
More on NCT06885281
-
Trial result · Apr 30, 2026
ZL-1310 (DLL3-targeted topo-I ADC) drives 48% ORR in platinum-refractory extrapulmonary NEC (early Phase 1b)
More in neuroendocrine and adrenal tumors
-
Trial result · Oct 15, 2026 · NCT00107289
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma -
Trial result · Aug 27, 2026 · NCT03972488
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs -
New trial · Aug 27, 2026 · NCT07743138
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL -
Trial result · Aug 6, 2026 · NCT03049189
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE) -
New trial · Jul 16, 2026 · NCT07661420
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs